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Summary A total of 458 eligible patients, from 21 centres, with histologically or cytologically confirmed
SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two
regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three
courses (ECMV3) or six courses (ECMV6). In the third regimen, etoposide and ifosfamide were given for six
courses (EI6). Patients with limited disease (56% of the total) also received radiotherapy to the primary site
after the third course ofchemotherapy in all three groups. A partial response occurred in 45% of 144 ECMV3
patients, 48% of 141 ECMV6, and 53% of 141 E16 patients assessed, and a complete response in a further
15%, 9%, and 13% respectively, giving total response rates of 60%, 57%, and 67%, respectively. There was
no overall survival advantage to any of the three regimens. At 1 year, 24%, 29%, and 30% of patients were
alive, and at 2 years 7%, 8%, and 9%, respectively. The median survival time was 7.4 months in the ECMV3
group, 8.6 months in the ECMV6 group and 8.8 months in the E16 group. The individual factors: poor
performance status, extensive disease, the presence of dysphagia and a raised white blood cell count on
admission adversely affected prognosis. The results do not exclude the possibility of a minor survival
advantage with the two 6-course regimens. The findings on quality of life are presented in the companion
paper (MRC Lung Cancer Working Party, 1993b).
It is well established that small cell lung cancer initially
responds well to combinations of cytotoxic drugs and
radiotherapy, although long-term survival rates are low. The
aims of treatment are to control symptoms and prolong
survival. Treatment may induce its own morbidity and it is
therefore undesirable to continue it for longer than is neces-
sary.
If the tumour responds, the maximum response, complete
or partial (World Health Organization, 1979), is usually
achieved after only two or three courses of chemotherapy.
Several randomised trials have therefore attempted to deter-
mine the minimum number of courses of chemotherapy that
can be given without compromising survival. At the time the
present trial was being planned, the Midlands Small Cell
Lung Cancer Group (Cullen et al., 1986) were conducting a
trial in which patients who achieved a response to induction
chemotherapy with six courses of vincristine, doxorubicin,
and cyclophosphamide were randomly allocated to a further
eight courses of maintenance chemotherapy or to no further
chemotherapy until relapse. In a trial by the EORTC
(European Organization for Research and Treatment of
Cancer) (Splinter, 1988), patients who responded to five
courses of cyclophosphamide, doxorubicin, and etoposide
were being randomly allocated to a further seven courses of
chemotherapy or symptomatic treatment alone, and in a trial
by the London Lung Cancer Group (Harper et al., 1987),
patients were being randomly allocated to eight or four
courses of etoposide, cyclophosphamide and vincristine
(ECV), and there was a second randomisation to further
chemotherapy with doxorubicin and methotrexate or to
symptomatic treatment alone at the time of relapse. In a
previous trial conducted by the Medical Research Council
(MRC Lung Cancer Working Party, 1989), patients with a
response to induction chemotherapy with six courses of
etoposide, cyclophosphamide, methotrexate, and vincristine
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were randomly allocated to a further six courses or no fur-
ther chemotherapy. An interim analysis available at the time
the present trial was planned, showed that there was no
overall survival advantage to either treatment group.
The main aim of the present randomised trial was to
investigate whether six courses of etoposide, cyclophos-
phamide, methotrexate, and vincristine (ECMV6), which was
one of the regimens of the previous MRC trial, could be
reduced to three courses (ECMV3) without compromising
survival. The intention was to compare these two durations
as primary treatment policies. The randomisation to three or
six courses was therefore made on admission and not after
the third course. A second aim was to compare these
regimens of a drug combination that was accepted as stan-
dard vs six courses of etoposide and ifosfamide (EI6). This
was a new regimen that was showing promisingly high res-
ponse rates in phase II trials (for example, Thatcher et al.,
1987). As it had not previously been assessed in a ran-
domised trial, it was decided not to study it for less than six
courses. The end-points for assessment were control of the
disease, adverse effects and quality of life.
The findings on response, survival, prognostic factors and
the development of metastases are presented in this report;
those on adverse effects and quality of life are presented in a
separate report (MRC Lung Cancer Working Party, 1993b),
hereinafter referred to as Paper 2.
Methods
Eligibility
Patients of either sex aged 75 years or less were eligible for
the trial if they had previously untreated, histologically or
cytologically confirmed small cell lung cancer of any extent.
They had to have normal renal function, and no major
disturbance of liver function (plasma bilirubin concentration
not higher than twice the upper limit of the normal range for
the local laboratory), and no other previous or concomitant
malignant disease except basal cell carcinoma or in situ car-
cinoma of the cervix. Patients were ineligible if they had
evidence of brain metastases, or any disease contraindicating
chemotherapy or radiotherapy. Patients with a poor perfor-
mance status were eligible only if this was due to an
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unrelated condition or to a cause, such as inappropriate
ADH secretion, likely to respond to chemotherapy. Local
ethics committee approval of the protocol and individual
patient consent were required.
Histological or cytological diagnosis
The diagnosis was made by the histopathologist from the
referring centre according to the WHO classification (World
Health Organization, 1981) on a specimen obtained from
bronchial, pleural, lung, mediastinal, or lymph node biopsy,
bronchial brushings, or sputum or fine needle aspirate
cytology. The specimens were later examined by a single
reference histopathologist for confirmation of the cell type.
Treatment allocation
Patients were randomly allocated by the MRC Trials Office
to one of three treatment regimens using a minimisation
procedure, stratifying for admitting clinician and for limited
or extensive disease. When the extent of disease was not
known at the time of randomisation, the patient was
stratified in a separate category.
ECMV3 The ECMV3 regimen comprised three courses of
chemotherapy, each course given on 3 consecutive days at
3-week intervals. On day 1 etoposide 120 mg m2 was given
by intravenous infusion over 30 min, together with cyclo-
phosphamide 1 g m-2, methotrexate 35 mg m-2 and vincris-
tine 1.3 mg m-2 (maximum dose 2.0 mg) by intravenous
injection. On days 2 and 3 etoposide 120 mg m-2 intra-
venously or 240 mg m-2 by mouth was given. Patients with
limited disease were also given megavoltage radiotherapy to a
midline dose of 40 Gy in 15 daily fractions over 3 weeks
starting 3 weeks after the third course of chemotherapy. It
was delivered through planned portals to the primary site
and mediastinal lymph nodes, the field extending at least
from the suprasternal notch to 3 cm below the carina and
encompassing the full width of the mediastinum and lung
hila.
ECMV6 The ECMV6 regimen comprised six courses of the
same chemotherapy as the ECMV3 regimen. Patients with
limited disease also received thoracic radiotherapy, as above,
after the third course of chemotherapy, the fourth course
being given 3 weeks after the end of radiotherapy.
EI6 The E16 regimen comprised six courses of chemo-
therapy, each course given on three consecutive days at
3-week intervals. Etoposide was given as above. On day 1 it
was followed by ifosfamide S g m2 plus mesna 5 g m2,
mixed together, by intravenous infusion over 24 h. On day 2
the etoposide was followed by mesna 3 g mr2 by intravenous
infusion over 12 h. If the etoposide was given orally, the
mesna could be given orally, 2 g m-2 being given three times
at intervals of 4 h. Patients with limited disease also received
the same thoracic radiotherapy as in the ECMV6 regimen,
after the third course of chemotherapy, the fourth course
being given 3 weeks after the end of radiotherapy.
Reports and investigations
The pretreatment assessment included clinical examination, a
postero-anterior chest radiograph, measurement of the blood
haemoglobin and plasma urea, creatinine, and bilirubin con-
centrations, and total white blood cell and platelet counts.
The extent of disease, as assessed on clinical and radio-
graphic evidence, was recorded as either limited to the soft
tissues of one hemithorax, the mediastinum and the ipsi-
lateral and contralateral scalene and lower cervical lymph
nodes (limited disease), or more extensive than this (extensive
disease).
A report was also completed at each attendance for treat-
ment, then monthly up to 12 months and then once every 3
months. These reports included details of the treatment
given, the response to treatment, partial or complete (World
Health Organization, 1979), metastases, and the results of the
same investigations as were done pretreatment. At death, the
certified cause was reported and, if an autopsy was done, the
findings.
Assessment ofphysical condition by clinicians
The clinician's assessments of the patient's overall condition,
performance status and degree of breathlessness were
recorded at each attendance according to the categories
shown in Table I. The clinician also asked the patient about
the occurrence and severity of cough, haemoptysis, chest
pain, anorexia, dysphagia, pain in sites other than the chest,
and of possible adverse effects of treatment, recording the
answers as none, mild, moderate, or severe.
Statistical methods
The Kaplan-Meier estimate was used to calculate survival
curves and the Mantel-Cox version of the log-rank test to
make treatment comparisons. Survival was calculated from
the date of randomisation until death or date last known to
be alive. The metastasis-free survival time, in patients with
limited disease, was calculated from randomisation until the
first appearance of metastases. Patients who died before
metastases were detected were censored. Associated con-
fidence intervals (CI) for the corresponding hazard ratios
(HR) were calculated as described in Machin and Gardner
(1989). The effect of factors for prognosis on survival was
assessed by a proportional hazards regression model as des-
cribed in, for example, Altman (1991). The trial data were
managed using the COMPACT programme (COMPACT
Steering Committee, 1991).
Results
Patients in the trial
Between February 1985 and April 1989, 491 patients (165
ECMV3, 163 ECMV6, 163 E16) were admitted from 21
centres in the United Kingdom. There were 33 patients (8
ECMV3, 11 ECMV6, 14 E16) who were subsequently
regarded as ineligible, 24 because the reference histo-
pathologist considered that their histology was not small cell
lung cancer and the remaining nine, because they were
entered in error: two had had previous malignant disease,
two had brain metastases, two had already received treat-
ment, two had been randomised against their consultant
clinician's wishes, and one was aged over 75. According to
our practice at the time, no follow-up data, other than the
date of death, were routinely collected on these 33 patients
and they are omitted from all the analyses presented in this
report except survival (see Table II). There remain 458
patients (157 ECMV3, 152 ECMV6, 149 EI6) for analysis.
The characteristics of the patients on admission are shown
in Table I. The overall condition, performance status, and
degree of breathlessness were normal or nearly normal (grade
0 or 1) in 62%, 63%, and 52%, respectively. In addition,
most (84%) of the patients had cough, 31% had hae-
moptysis, 47% chest pain, 51% anorexia, and 8% dysphagia
(Paper 2). The distributions of these variables were similar in
the three treatment groups.
Protocol treatment received
In all, 296 patients (127 (81%) ECMV3, 84 (55%) ECMV6,
85 (57%) E16) completed their allocated courses of chemo-
therapy and radiotherapy, although 80 (20 ECMV3, 36
ECMV6, 24 EI6) of them experienced delays, reductions in
dosages and/or the omission of one or more drugs because of
toxicity. A further 15 patients (five ECMV3, three ECMV6,
seven E16) never started their allocated regimen, although
three ECMV3 patients were given El and two E16 patients1152 MRC LUNG CANCER WORKING PARTY
Table I Characteristics of the 458 patients on admission
ECMV3 ECMV6 E16 Total
Characteristic No. (%) No. (%) No. (%) No. (%)
Sex
male
female
Age (years)
-44
45-54
55-64
65-75
Extent ofdisease
limited
extensive
Overall condition
0. excellent
1. good
2. fair
3. poor
4. very poor
not known
Performance status
(WHO, 1979)
0. normal, without
restriction
1. strenuous activity
restricted, can do
light work
2. up and about > 50%
ofwaking hours,
unable to work,
capable of all
self-care
3. confined to bed or
chair > 50% of
waking hours,
limited self-care
4. confined to bed or
chair, no self-care
not known
Degree ofbreathlessness
0. climbs hills or stairs
without dyspnoea
1. walks any distance on
flat without dyspnoea
2. walks over 100 yards
without dyspnoea
3. dyspnoea on walking
100 yards or less
4. dyspnoea on mild
exertion, e.g.
undressing
not known
103
54
8
24
62
63
90
67
15
75
55
8
1
3
28
68
(66)
(34)
(5)
(15)
(39)
(40)
(57)
(43)
(10)
(49
(36)
(5)
(1)
102 (67)
50 (33)
8 (5)
22 (14)
71 (47)
51 (34)
84 (55)
68 (45)
18 (12)
76 (51)
43 (29)
9 (6)
2 (1)
4
(18) 27 (19)
(44) 63 (43)
97 (65)
52 (35)
4 (3)
22 (15)
74 (50)
49 (33)
82 (55)
67 (45)
20 (14)
72 (50)
38 (26)
14 (10)
1 (1)
4
29
65
(20)
(45)
302 (66)
156 (34)
20 (4)
68 (15)
207 (45)
163 (36)
256 (56)
202 (44)
53 (12)
223 (50)
136 (30)
31 (7)
4 (1)
11
84 (19)
196 (44)
46 (30) 38 (26) 32 (22) 116 (26)
10 (7) 15 (10)
4
27
45
37
33
10
S
(1) 2 (1)
7
(18)
(30)
(24)
(22)
(7)
22 (15)
54 (37)
36 (24)
27 (18)
8 (5)
5
17 (12) 42 (10)
1
35
46
35
20
11
(1)
(24)
(31)
(24)
(14)
(7)
2
4 (1)
16
84 (19)
145 (33)
108 (24)
80 (18)
29 (7)
12
Table II Survival from randomisation
Unadjusted
Median Deaths hazard
survival Observed Expected ratio
Regimen Patients (days) (0) (E) OIE (HR)
Eligible patients
ECMV3 157 225 153 139.5 1.10 1
ECMV6 152 263 143 148.7 0.96 0.87
EI6 149 269 146 153.9 0.95 0.86
Allpatients
ECMV3 165 227 160 150.1 1.07 1
ECMV6 163 266 153 156.2 0.98 0.92
E16 163 264 157 163.7 0.96 0.90
The 95% CIs for the adjusted HRs are shown in Table III.
ECMV in error. Also, 60 patients (14 ECMV3, 27 ECMV6, Treatmentfor relapse
19 E16) died during treatment, and the remaining 87 (11
ECMV3, 38 ECMV6, 38 EI6) had their allocated regimen Sixty-two patients (32 ECMV3, 18 ECMV6, 12 EI6) received
stopped prematurely, 39 because of adverse effects, 45 additional chemotherapy, and 125 (52 ECMV3, 34 ECMV6,
because of progressive disease, and three in error. 39 E16) radiotherapy for relapse.DURATION OF CHEMOTHERAPY IN SCLC 1153
Initial response to treatment
The initial response to treatment was assessable from clinical
and radiographic findings in 144 ECMV3, 141 ECMV6, and
141 EI6 patients, during the first three courses of chemo-
therapy and before any radiotherapy was given. Response
was partial in 65 (45%), 68 (48%), and 75 (53%), and
complete in 22 (15%), 13 (9%), and 19 (13%), respectively.
The total response rates were thus 60%, 57% and 67%,
respectively. Patients who died during this period were
classified as non-responders.
Survival
Follow-up is complete for all of the 458 eligible patients up
to at least 4 years from the date of allocation. The survival
comparison by regimen is shown in Figure 1 and is sum-
marised in Table II. The table indicates a small disadvantage
for the ECMV3 group compared with the other two, but no
evidence of a difference between the ECMV6 and E16 groups
(HR = 0.87 and 0.86 respectively compared with ECMV3).
However, the Mantel-Cox test gives X2 = 1.00, df= 2, and
P = 0.6, indicating no statistically significant differences
between the treatment groups. (See also the analysis sum-
marised in Table III described below.) At 1 year, 24%, 29%,
and 30% of patients were alive, and at 2 years 7%, 8%, and
9%, respectively. There was little difference in the median
survival times, these being 225 days (7.4 months) in the
ECMV3 group, 263 days (8.6 months) in the ECMV6 group
and 269 days (8.8 months) in the EI6 group. The small
advantage to the 6-course regimens was most evident in
patients showing a response to chemotherapy (HR=0.80
and 0.79) than in non-responders (HR = 1.20 and 1.01).
The estimated HRs of Table II were little affected follow-
ing separate stratified analyses for the known prognostic
factors: performance status and extent of disease on admis-
sion; albeit, each had prognostic influence on survival. Their
individual effects on prognosis, with all three treatment
groups combined, are illustrated in Figure 2. Thus, prognosis
clearly reflects the gradient of performance status and
patients with extensive disease were at a disadvantage com-
pared with those with limited disease.
These variables, together with the remaining potential
prognostic variables recorded at randomisation, were inves-
tigated using the Cox proportional hazards model to see if
they were of independent importance. Missing data were
assigned to a separate category for each variable. This
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analysis (Table III) suggested that both performance status
and extent of disease when taken together remained of prog-
nostic importance. For a baseline performance status of
grade 0 or 1, the HR for grade 2 or 3 is 1.87 and for grade 4
it is 4.55. This means, for example, that patients with a grade
4 performance status at randomisation had a 4.55 greater
death rate than those with grade 0 or 1. The two variables
adversely affected prognosis in the sequence poor perfor-
mance status and extensive disease. In addition, there was an
indication that patients with dysphagia (HR = 1.35) and with
a white blood cell count greater than 10,000 mm 3
(HR = 1.31) had a worse prognosis (Figure 2) although the
respective CIs were wide (Table III). As expected, patients
for whom these variables were not recorded, for whatever
reasons, take intermediate positions.
The adjusted HR for the treatment effects and the
associated 95% confidence intervals are also indicated in
Table III. Even allowing for the above prognostic factors,
there was no significant survival benefit for any of the three
regimens, nor for six as opposed to three courses of
chemotherapy. These conclusions are unaffected if the 33
ineligible patients are included in the survival analysis (Table
II).
Early death was much more likely to occur in patients with
poor performance status pretreatment, especially if they also
had extensive disease (Table IV). Moreover, the times of
death were clustered in the second week after the date of
start of chemotherapy; 25 of the 41 occurred during that
week compared with eight during the first week and eight
during the third week.
Cause ofdeath
Of the 421 patients (146 ECMV3, 140 ECMV6, 135 EI6)
who died within 2 years of randomisation, 407 were certified
as having died from their cancer. In a further eight (three
ECMV3, two ECMV6, three E16), toxicity was recorded as a
major contributing factor. Five (one ECMV3, two ECMV6,
two E16) died from other causes, and in the remaining
patient (ECMV3) the cause of death was unknown. Data on
residual tumour at the primary site were available on 376
patients (130 ECMV3, 125 ECMV6, 121 E16), of whom 89
(68%), 77 (62%), and 74 (61%), respectively, had residual
tumour, and of these, 78 (88%), 68 (88%), and 63 (85%) in
the three treatment groups respectively, also had distant
metastases.
- ECMV3 (157 patients)
ECMV6 (152 patients)
- E16 (149 patients)
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Figure 1 Percentage of patients surviving from the date of randomisation.1154 MRC LUNG CANCER WORKING PARTY
Table III The Cox regression model to assess the influence of baseline variables on the
treatment comparisons (based on the 458 eligible patients)
Adjusted
Regression Standard hazard
coefficient error ofb ratio
Variable b s.e.(b) b/s.e.(b) (HR) 95% CI
Regimen
ECMV3 0 - - 1 -
ECMV6 -0.123 0.120 -1.02 0.88 0.70-1.12
E16 -0.149 0.116 -1.28 0.86 0.69-1.08
Performance status
grade 0,1 0 - - 1
2,3 0.626 0.108 5.78 1.87 1.51-2.31
4 1.515 0.516 2.93 4.55 1.65-12.52
Unknown 0.709 0.350 2.03 2.03 1.02-4.03
Extent ofdisease
Limited 0 - - 1
Extensive 0.654 0.103 6.37 1.92 1.57-2.35
Dysphagia
Absent 0 - - 1
Present 0.302 0.128 1.66 1.35 0.95-1.93
Unknown - 0.085 0.334 - 0.26 0.92 0.48-1.77
White cell count
(1,OOOs mm-3)
<10 0 - - 1
10 + 0.268 0.102 2.62 1.31 1.07-4.70
Unknown 0.655 0.456 1.44 1.93 0.79-4.70
Performance status (WHO Grade)
Dysphagia
'I. No dysphagia (407 patie
--k ----- Dysphagia (34 patients)
---- Not recorded (17 patient
.
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Time from randomisation (months)
Extent of disease
Limited (256 patients)
---- Extensive (202 patients)
Blood white cell count
<10 (289 patients)
---- 10+ (164 patients)
--- Not recorded (5 patients)
12 18 24
Figure 2 Percentage of patients surviving from the date of randomisation according to WHO performance status, extent of disease, dysphagia, and blood total white cell count on admission.
Table IV Deaths within 3 weeks ofstarting chemotherapy by extent of
disease and performance status
Performance Extent ofdisease
status Limited Extensive Total
0 1/54 (2%) 0/30 (0%) 1/84 (1%)
1 4/126 (3%) 3/70 (4%) 7/196 (4%)
2 7/54 (13%) 11/62 (18%) 18/116 (16%)
3 1/14 (7%) 10/28 (36%) 11/42 (26%)
4 0/0 2/4 (50%) 2/4 (50%)
Unknown 1/8 1/8 2/16
14/256 (5%) 27/202 (13%) 41/458 (9%)
Development ofmetastases in patients with limited disease on
admission
Among the 256 patients with limited disease on admission,
metastases were reported as developing in 213 (83%). In 180
(63 ECMV3, 56 ECMV6, 61 E16) they were considered
definite, and in the remaining 33 (13 ECMV3, nine ECMV6,
11 E16) suspected. Definite liver metastases were reported in
34 (13%) patients (16, 12 and six, respectively), definite brain
metastases in 51 (20%) patients (17, 14 and 20, respectively),
and definite bone metastases in 46 (18%) patients (17, 14 and
15, respectively). Thus, metastases developed in similar pro-
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portions in the three treatment groups, although the median
time to their first appearance was 177 days in the ECMV3
group compared with 214 and 233 days, or 1 to 2 months
later, in the ECMV6 and E16 groups, respectively (X2 = 4.85,
df = 2, P = 0.09, Mantel-Cox test).
Discussion
The present trial, involving 458 patients, is one of a number
of randomised clinical trials that have recently investigated
the optimum duration of chemotherapy in the treatment of
small-cell lung cancer. Their aim has been to define the
minimum amount of chemotherapy necessary to achieve the
best possible effect on survival, thereby keeping the adverse
effects of chemotherapy to a minimum. There was no statis-
tically significant survival advantage to any of the treatment
groups: etoposide, cyclophosphamide, methotrexate, and vin-
cristine for three courses (ECMV3) or for six courses
(ECMV6), or etoposide and ifosfamide for six courses (E16).
Nevertheless, the data are not inconsistent with the pos-
sibility of a 10% greater death-rate (HR = 1.1) with the
three-course regimen compared with the six-course regimens,
but to confirm such a difference with the same test size and
power would require a randomised comparison involving at
least 4,000 patients. The size of the differences was small: I
month median survival time, a difference of questionable
clinical importance. As in previous trials comparing different
treatment durations, the small advantage to the longer dura-
tion was most evident in patients showing a response to
chemotherapy (MRC Lung Cancer Working Party, 1989;
Spiro et al., 1989). Response rates and the proportions of
patients in whom metastases appeared were similar in the
three groups although metastases tended to appear sooner in
the three-course group than in the six-course groups.
Survival was somewhat shorter than has been reported by
some other cooperative groups, but was similar to that in
other large national studies. Such studies are probably more
representative of the patient population as a whole (reviewed
by Hansen, 1992). The results are also similar to those
reported in the comparable trials conducted in the UK. They
need to be interpreted together with those from the other
comparable trials investigating the optimum duration of
chemotherapy. In a previous Medical Research Council trial
(MRC Lung Cancer Working Party, 1989), 265 patients res-
ponded to initial chemotherapy with six courses of etoposide,
cyclophosphamide, methotrexate, and vincristine, and were
then allocated at random to a further six courses of the same
chemotherapy or to no further chemotherapy until relapse.
There was no evidence of an overall survival advantage to
either group. Nevertheless, there was a suggestion that
maintenance chemotherapy prolonged survival in patients
with a complete response at the time of randomisation.
In the trial conducted by the Midlands Small Cell Lung
Cancer Group (Cullen et al., 1986), 93 patients responded
well to induction chemotherapy with six courses of vincris-
tine, doxorubicin, and cyclophosphamide, and were allocated
at random to a further eight courses of maintenance
chemotherapy or to no further chemotherapy until relapse.
Maintenance chemotherapy significantly prolonged survival
in the patients with extensive disease on admission, but in the
patients with limited disease, survival was longer in the no
maintenance group, although this difference was not statis-
tically significant.
The London Lung Cancer Group (Spiro et al., 1989)
allocated 616 patients at random to receive either four or
eight courses of etoposide, cyclophosphamide, and vincris-
tine, and at relapse to receive either symptomatic treatment
or further chemotherapy using drugs other than those used
initially. There were thus four patient groups compared. The
only survival difference found was that survival was
significantly shorter in patients allocated to receive four
courses of initial chemotherapy without further chemo-
therapy on relapse; the difference was greatest in the respon-
ding patients, but even this difference was small. The authors
concluded that if only four courses of chemotherapy were
given, there was a survival disadvantage unless patients
received chemotherapy on relapse, but if eight courses were
given initially, then there was no advantage from giving
further chemotherapy at relapse. They emphasised, however,
that the policy of giving chemotherapy on relapse was
difficult to apply because patients and physicians were often
reluctant to restart chemotherapy.
In the trial undertaken by the EORTC (Giaccone et al.,
1993), 434 patients responded to initial chemotherapy with
five courses of cyclophosphamide, doxorubicin, and eto-
poside, and were then allocated at random to conservative
treatment only or a further seven courses of the same
chemotherapy. Although the time to progression was
significantly prolonged by maintenance chemotherapy, there
was no survival advantage to either group.
In the light of all these findings it seems reasonable to
conclude that in terms of the duration of survival six courses
of chemotherapy should be accepted as a maximum (Spiro &
Souhami, 1990). Nevertheless, an important conclusion, par-
ticularly in the light of the comparison of six vs three courses
in the present trial, is that current chemotherapy regimens
achieve almost all of their potential action during the first
three courses. This implies that clinicians should aim to give
these three courses without interruption or modification.
In the present trial, a number of characteristics affected
prognosis. Poor performance status and extensive disease at
the time of randomisation had an adverse influence,
confirming findings from previous studies (Rawson & Peto,
1990). Dysphagia, suggesting a centrally situated tumour or
mediastinal extension, had an adverse effect, as did a white
blood cell count above 10,000 mm-', suggesting the presence
of infection or marrow infiltration. Moreover, the survival
curves show that much of the adverse effect of these factors
was seen within a month of randomisation. Rawson and Peto
included white blood cell count in their analysis but did not
have data available on dysphagia or other symptoms.
Analyses of prognostic factors need to continue because pro-
gnostic indicators not previously investigated may yet be
identified. We are also undertaking an updated analysis on
data from the trials studied by Rawson and Peto. This will
have the advantage ofincluding larger numbers of events and
hence of increasing statistical power.
As in earlier trials (MRC Lung Cancer Working Party,
1989; Morittu et al., 1989), a substantial number of deaths in
the present trial occurred shortly after the start of treatment.
The times of these deaths were closely clustered in the second
week after the date of start of the first course of
chemotherapy, the period when the peripheral white blood
cell count is likely to have been at its lowest. This also
suggests that infection could be an important contributory
cause of these early deaths, and that the routine use of
prophylactic antibiotics during chemotherapy, especially in
patients in the poor prognostic group, could help to prevent
them (Morittu et al., 1989). Such a policy has now been
adopted by the MRC Lung Cancer Working Party. Patients
with adverse prognostic indicators need close supervision
during the early weeks of chemotherapy if these early deaths
are to be reduced or avoided.
In the present trial (Paper 2) the frequency and severity of
adverse effects of treatment were very similar in the three
treatment groups. About two thirds of the patients in all
three groups were reported by their clinicians to have
experienced moderate or severe adverse effects, the com-
monest of which were anorexia, myelosuppression, dys-
phagia, and vomiting. Both drug combinations were highly
effective in palliating the symptoms of the disease. The pro-
portions of patients with improvement in overall condition,
performance status, and breathlessness were somewhat higher
in the EI6 than in the two ECMV groups, but this small
advantage needs to be weighed against the inconvenience of
the 24-h infusions required compared with the 30-min
infusions of the ECMV regimens.
The results of this trial support the view that is generally
becoming accepted that intensive chemotherapy is indicated1156 MRC LUNG CANCER WORKING PARTY
for patients in whom tumour control is a realistic medium-
term goal, and that less toxic palliative chemotherapy, or
indeed radiotherapy, should be considered for patients with
poor performance status and advanced disease (Hansen,
1992). In line with this policy, the MRC Lung Cancer Work-
ing Party is currently investigating the feasibility of dose
intensification with haemopoietic growth-factor support in
the better prognosis group. In the poor prognosis group, we
are investigating the implications for quality of life and sur-
vival if the four-drug regimen (ECMV) is reduced to a
two-drug regimen of etoposide and vincristine as palliative
chemotherapy (LU12 protocol), and are also comparing
single-drug orally administered etoposide vs standard intra-
venous chemotherapy (LU16 protocol). There is still a case
for investigating whether patients in the worst prognostic
groups should be given any chemotherapy.
The following consultants and their colleagues entered 20 or more
patients into the trial: Brighton: J.P.R. Hartley, N.J. Hodson, C.W.
Turton; Bristol: V.L. Barley, J.A. Bullimore, R.J. White; Cambridge:
N.M. Bleehan, M.V. Williams; Cork: C.P. Bredin; Kettering: A.R.
Davidson, T.J. Williams; Leeds: D.V. Ash, H.J. Close, C.A. Joslin,
M.F. Muers, J. Stone; Mount Vernon: R.F. Ashford, S. Dische, E.P.
Dunphy, D.C. Fermont, E. Grosch, E.J. Maher, M.I. Saunders;
Oxford: R.J. Adam, C.J. Alcock, M.K. Benson, J.M. Hopkin, D.J.
Lane; York: A.M. Hunter.
The remaining patients were entered by the following consultants
and their colleagues: Carluke: J.C.J.L. Bath; Chesterfield: J.W.
Hadfield; Inverness: W.D. Murray; Ipswich: C.R. Wiltshire; Mid-
dlesex: R. Berry, A.M. Jelliffe, A.R. Makepeace, M.F. Spittle; Mil-
ton Keynes: S. Fisher; Northampton: G.C. Ferguson; Plymouth:
J.M. Brindle, A.F. Broad, C.R. McGavin; Sheffield: J.J. Bolger, A.E.
Champion, K. Dunn, I.H. Manifold; Stoke Mandeville: S.J. Wil-
liams; Swindon: J.A. Waddell; Wolverhampton: D.J. Fairlamb.
The reference histopathologist was P.G.I. Stovin. Local coor-
dinators were: A. Anderson, R. Collins, L. Crossley, C. des Rochers,
A. Fenwick, S. Garner, L. Grant, C. Hutchinson, V. Marmur, A.
Pickett, D. Robinson, C. Shuerman, K. Weiner, T. Young.
The MRC Trials Office data managers were: Elizabeth Brodnicki,
Grazyna Lallemand and Sheila Thornton.
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